|
EHE Operations Leadership Team (OLT)
|
Committee, Work group, Advisory group, or Task Force
|
OASH, CDC, HRSA, IHS, SAMHSA, CMS
|
NIAID, NIMH, OD/DPCPSI/OAR
|
This is a multi-agency steering committee of HHS' EHE initiative. The charge of the OLT is to monitor the progress of the EHE initative, exchange information, contribute critical thinking to the strategies and partnerships for the program
|
|
Emergency Preparedness, Medical Countermeasures
|
Resource Development
|
ASPR, CDC
|
NCI
|
The National Cancer Institute (NCI) provides expertise in radiation biology and radiation oncology to help guide the research and development of medical countermeasures for radiation injury and for biomarkers for assessing injury, dose, and who needs treatment. NCI also provides expertise in disaster preparedness and response to ASPR for radiological and nuclear incidents.
|
|
Emerging Tobacco Products Communication Initiative Subject Matter Expert Work Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIMHD
|
The Subject Matter Experts workgroup provides input to CDC’s communication initiative on preventing and reducing use of emerging tobacco products through a multimedia campaign targeting educators. This workgroup is organized by the CDC Office on Smoking and Health.
|
|
End-stage Renal Disease Collaboration
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NIDDK, NIBIB
|
Participating agencies and patient and physician groups are collaborating to help the medical product development community to understand the challenges and milestones needed to achieve the goal of a successful alternative to dialysis. Research, regulatory, and reimbursement needs for such a product are discussed in phone calls and structured meetings.
|
|
Ending the HIV Epidemic in the US administrative supplement announcement for NIH Centers for AIDS Research and NIMH AIDS Research Centers
|
Research Initiative
|
CDC, HRSA
|
NIAID, NIMH, OD/DPCPSI/OAR
|
The NIH CFAR and NIMH ARC EHE administrative supplements support implementation research by addressing the four key pillars of the EHE initiative (Diagnose, Treat, Prevent, and Respond). Specifically, the NIH will support CFAR/ARC investigators to conduct research in collaboration with local partners funded by the participating HHS agencies to support local EHE plans. CDC and HRSA ;provided key support in the development of the research topics.
|
|
Endocrinologic and Metabolic Drugs Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NIAID
|
The Endocrinologic and Metabolic Drugs Advisory Committee (the Committee) advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which the Food and Drug Administration (FDA) has regulatory responsibility.
|
|
Enhancing Scientific Collaboration between US and Colombia
|
Committee, Work group, Advisory group, or Task Force
|
OGA
|
NIA, NIAID, FIC
|
The Office of the Americas of the HHS has formed a group consisting of representatives from NIAID, FIC, and NIA to foster communication with the goal of enhancing scientific collaboration between US and Colombia.
|
|
Environmental Phthalate Exposures in Pregnancy in Relation to Fetal and Placental Development
|
Research Initiative
|
CDC
|
NIEHS
|
The purpose of this collaboration is to characterize exposure to phthalates and phthalate alternatives in pregnant women by measuring phthalate and phthalate alternative metabolites in urine samples from 8 visits in pregnancy. We will examine associations between these markers and fetal growth as well as ultrasound measures of placental development.
|
|
eRA Federal Shared Services (eRA)
|
Resource Development
|
AHRQ, FDA, SAMHSA
|
OD/OER
|
Collaboration with other HHS agencies and federal agencies to provide electronic Research Administration (eRA) grants management services and support across the full grants life cycle.
|
|
Establishment of representative examination and dose repository for patients undergoing interventional fluoroscopic procedures
|
Research Initiative
|
FDA
|
NCI
|
NCI and FDA investigators are collaborating to establish representative examination and organ doses for fluoroscopically-guided interventional procedures by collecting anonymized patient data from multiple US clinical institutions.
|